BTIG Research restated their neutral rating on shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a report released on Thursday.

A number of other brokerages have also recently weighed in on REGN. Goldman Sachs Group Inc. reissued a buy rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 10th. Leerink Swann set a $511.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a buy rating in a research note on Saturday, August 6th. RBC Capital Markets reaffirmed a buy rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, August 6th. Piper Jaffray Cos. set a $447.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a hold rating in a research note on Sunday, October 30th. Finally, Cowen and Company set a $430.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a hold rating in a research note on Sunday, October 30th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have given a buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of Hold and a consensus price target of $468.87.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.735% during midday trading on Thursday, reaching $407.535. The company’s stock had a trading volume of 157,857 shares. The firm has a market capitalization of $42.72 billion, a P/E ratio of 59.459 and a beta of 1.79. The company’s 50-day moving average is $381.02 and its 200 day moving average is $388.09. Regeneron Pharmaceuticals has a 52 week low of $325.35 and a 52 week high of $587.38.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, November 4th. The biopharmaceutical company reported $3.13 EPS for the quarter, beating the Zacks’ consensus estimate of $2.73 by $0.40. The firm earned $1.22 billion during the quarter, compared to the consensus estimate of $1.29 billion. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The firm’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the firm earned $3.47 earnings per share. Analysts expect that Regeneron Pharmaceuticals will post $11.73 earnings per share for the current fiscal year.

In other news, Director Joseph L. Goldstein sold 2,125 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $450.00, for a total transaction of $956,250.00. Following the completion of the sale, the director now owns 15,125 shares in the company, valued at approximately $6,806,250. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $429.34, for a total value of $858,680.00. Following the sale, the director now owns 36,500 shares of the company’s stock, valued at approximately $15,670,910. The disclosure for this sale can be found here. Insiders own 10.40% of the company’s stock.

Several hedge funds have recently modified their holdings of REGN. LPL Financial LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter worth $1,233,000. Credit Suisse AG increased its stake in Regeneron Pharmaceuticals by 2.5% in the third quarter. Credit Suisse AG now owns 258,909 shares of the biopharmaceutical company’s stock worth $104,086,000 after buying an additional 6,236 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Regeneron Pharmaceuticals by 8.9% in the third quarter. Ameritas Investment Partners Inc. now owns 3,661 shares of the biopharmaceutical company’s stock worth $1,472,000 after buying an additional 298 shares during the last quarter. Candriam Luxembourg S.C.A. increased its stake in Regeneron Pharmaceuticals by 11.7% in the third quarter. Candriam Luxembourg S.C.A. now owns 106,210 shares of the biopharmaceutical company’s stock worth $42,699,000 after buying an additional 11,106 shares during the last quarter. Finally, Lombard Odier Asset Management Europe Ltd purchased a new stake in Regeneron Pharmaceuticals during the third quarter worth $384,000. Hedge funds and other institutional investors own 68.58% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.